The 29th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT 2026), the world's largest academic conference in gene and cell therapy, will be held in Boston, USA from May 12 to 16, 2026. It provides an international platform for participants to present the latest developments in gene and cell therapy and to engage in critical discussions.

Recently, five of China's latest research achievements in cell therapy have been accepted by ASGCT 2026. At this conference, Fosun Kairos, a holding subsidiary of Fosun Pharma will showcase three innovative products with 'first in class' or 'best in class' potential—FKC118 (enhanced CD19/CD20 CAR-T), FKC289 (BCMA/CD19 CAR-T manufactured using the innovative Fosunova-T platform), and FKC876 (Axicabtagene Ciloleucel Injection, CD19 CAR-T)—in collaboration with Ruijin Hospital affiliated with Shanghai Jiao Tong University School of Medicine. This joint presentation will highlight the latest breakthrough research findings, fully demonstrating Fosun Kairos's innovative breakthroughs and R&D strength in CAR-T cell therapy.

Five Latest Research Achievements To Be Presented at ASGCT 2026

FKC118（Enhanced CD19/CD20 CAR-T）

FKC118 is an enhanced autologous dual CAR-T product targeting both CD19 and CD20. Its dual-targeted CAR structure effectively mitigates the risk of relapse due to antigen escape. The innovative and optimized enhancement elements further boost the in vivo expansion and persistence of T cells, reducing the risk of relapse caused by diminished T cell function. This product is anticipated to deliver more durable and effective clinical benefits.

Abstract Title：An enhanced dual-targeting CD19/CD20 chimeric antigen receptor T cell therapy for B-cell malignancies

Presentation Type：Poster

Abstract Number：ASGCT1169 

Presentation Dates：May 11-15, 2026

Principal Investigators：Hai-Hua Gu, Rui-Na He, Wei-Wei Zhang, Ping Tan, Li-Yuan Jin

FKC289（BCMA/CD19 CAR-T manufactured using the innovative Fosunova-T platform)

This autologous dual-targeted CAR-T, manufactured by the innovative Fosunova-T platform, achieves deep and sustained remission in MM, ALA, MN and other autoimmune disorders, and it is expected to provide more efficient, safer, and standardized solutions for autoimmune diseases.

Abstract Title：Membranous Nephropathy Meets a Novel Anti-CD19 & Anti-BCMA Dual CAR-T Therapy that’s a First in Human Clinical Performance and Manufactured Using an Innovative Fosunova-T Platform

Presentation Type：Poster

Abstract Numbe：ASGCT1773

Presentation Dates：May 11-15, 2026

Principal Investigators：Wen-Shi Wang, Xi-Lin Chen, Yong Yang, Jian Zhang, Li Hou, He Xin, Li-Shen Wang, Ai-Dong Shan, Xiao-Chen Wang, Wen-Cui Chen, Jin-Zhou Guo, Xiao-Mei Wu, Xiang-Hua Huang, Zhi-Hong Liu

FKC289（Clinical Progress on MN FKC289-1）

As a BCMA&CD19 dual autologous CAR-T product, FKC289 achieves profound depletion of pathogenic plasma cells and/or B cells by simultaneously binding to BCMA and CD19 antigens. This mechanism enables treatment of plasma cell disorders and/or B cell-mediated autoimmune diseases. This pioneering study demonstrates initial efficacy and manageable safety in applying FKC289 to primary relapsed/refractory membranous nephropathy (MN), offering potential therapeutic benefits to broader patient populations.

Abstract Title：Efficacy and Safety of FKC289, a BCMACD19 dualtargeted CART therapy for refractory or relapsed PLA2R-associated Membranous Nephropathy

Presentation Type：Poster

Abstract Number：ASGCT1793

Presentation Dates：May 11-15, 2026

Principal Investigators：Xiang-Hua Huang, Wen-Cui Chen, Wei-Wei Xu, Jin-Zhou Guo, Xiao-Mei Wu, Da-Chang Chen, Wen-Hao Chen, Ai-Dong Shan, Yong Yang, Wen-Shi Wang, Zi-Song Zhou, Chris Wang, Wen Shi, Zhi-Hong Liu

Ruijin Hospital affiliated with Shanghai Jiao Tong University School of Medicine

TP53 mutation status does not impact CD19 CAR-T therapy efficacy or safety in the overall population; however, further analyses preliminarily suggest differential outcomes may arise from distinct co-stimulatory domains.

Abstract Title：Impact of TP53 mutation on CD19-Chimeric Antigen Receptor T-Cell Therapy in Large B-Cell Lymphoma

Presentation Type： Poster

Abstract Number：ASGCT1149

Presentation Dates：May 11-15, 2026

Principal Investigators：Ling-Shuang Sheng, Rong Shen, Zi-Xun Yan, Jing-Hua Zhao, Wei-Li Zhao, Li Wang

Ruijin Hospital affiliated with Shanghai Jiao Tong University School of Medicine

For patients with relapsed/refractory large B-cell lymphoma (R/R LBCL), bridging and immune maintenance therapy strategies, stratified by baseline tumor burden, can induce deeper early remission after CAR-T therapy, resulting in sustained disease control.

Abstract Title：Tumor Burden-Adapted Bridging Therapy Improves CD19 CAR-T Outcomes in Relapsed or Refractory Large B-cell Lymphoma: A Phase II, Single-Center Prospective Study

Presentation Type：Poster

Abstract Number：ASGCT720

Presentation Dates：2026年5月11-15日

Principal Investigators：Zi-Xun Yan, Niu Qiao, Shu-Bei Wang, Ling-Shuang Sheng, Rong Shen, Ting-Ting Pan, Qi Song, Xu-Feng Jiang, Hong-Mei Yi, Wen Wu, Li Wang, Shu Cheng, Peng-Peng Xu, Jing-Hua Zhao, Wei-Li Zhao

Matrix Synergy of Fosun Kairos's Core Technology Platforms

Accelerating Pipeline Development

Guided by the core philosophy of "Cure for Best Possible Life", Fosun Kairos is committed to delivering affordable, high-quality immunotherapy products to patients globally. Steadfastly adhering to the "first principles" thinking, we design R&D approaches from fundamental logic. Over the past year, Fosun Kairos has successfully established an enhanced multi-target engineered immune cell technology platform, a gene editing and gene delivery platform, a universal immune cell therapy platform, an LNP in vivo immunotherapy platform, and an LVV in vivo immunotherapy platform, forming a synergistic matrix to enhance R&D capabilities.

Meanwhile, Fosun Kairos actively embraces silicon-based intelligence and integrates AI to empower and accelerate cell therapy research and development. This approach ensures the success rate and accelerated conversion efficiency of individual project development across multiple dimensions, including early target screening, CAR structure design and optimization, enhancement element selection and verification, in vivo delivery specificity analysis, delivery system redesign, and narrowing the scope of wet experiments.

Currently centered on multi-target enhanced engineered multifunctional CAR-T, Fosun Kairos is advancing universal immune cell therapies, LNP and LVV as two in vivo immune cell therapies, and novel immune cell therapies to expand its R&D pipeline and develop globally competitive cell and gene therapy products. Additionally, the Company is actively developing gene editing and delivery technology platforms to continuously innovate, broaden new frontiers, and provide diverse immune cell therapies for patients worldwide with malignant tumors, autoimmune diseases, or chronic aging/inflammatory diseases, enhancing their quality of life and ensuring long-term survival benefits.